LogicBio Therapeutics, Inc. (LOGC)
| Market Cap | 266.76M |
| Revenue (ttm) | 2.91M |
| Net Income (ttm) | -37.19M |
| Shares Out | 23.60M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $8.36 |
| Previous Close | $8.45 |
| Change ($) | -0.09 |
| Change (%) | -1.07% |
| Day's Open | 8.48 |
| Day's Range | 8.26 - 8.72 |
| Day's Volume | 133,637 |
| 52-Week Range | 4.06 - 11.00 |
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...
Gene-editing concern LogicBio Therapeutics, Inc. has lost ~$90 million of market cap since an IND clinical hold was placed on its LB-001 candidate in February 2020. The hold was lifted in Augu...
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery ...
- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020 , with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 - Fast Track designation for LB-00...
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients Fast Track designation facilitates development of new therapi...
LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...
LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targete...
LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering target...
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...
LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –
FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Ped...
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3,...
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in ped...
LogicBio: A Speculative Buy For Their GeneRide Platform Based Gene Therapies
CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pedi...
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients – – Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 – – Established research collab...
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pedi...
About LOGC
LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collabor... [Read more...]
| Industry Biotechnology | IPO Date Oct 19, 2018 |
| CEO Frederic Chereau | Employees 41 |
| Stock Exchange NASDAQ | Ticker Symbol LOGC |
Analyst Forecasts
According to 4 analysts, the average rating for LOGC stock is "Strong Buy." The 12-month stock price forecast is 21.33, which is an increase of 155.14% from the latest price.